Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Biogen in up to $1.8 billion deal as rare diseases take center stage

Published 05/22/2024, 07:37 AM
Updated 05/22/2024, 10:22 AM
© Reuters. FILE PHOTO: Biogen logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration/File Photo
BIIB
-

(Reuters) -Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, bulking up on rare disease medicines as its older multiple sclerosis drugs face tepid demand due to rising competition.

Human Immunology's (HI-Bio) felzartamab has completed mid-stage studies for a type of kidney disease called primary membranous nephropathy, and in patients with a disease where the immune system makes antibodies that damage their transplanted organ.

The San Francisco-based company is also testing the therapy in patients with another chronic kidney disease known as IgA nephropathy. The therapy developer plans to conduct late-stage trials.

Since Christopher Viehbacher took the helm in late 2022, Biogen (NASDAQ:BIIB) has acquired rare disease drugmaker Reata for $6.5 billion, abandoned its controversial Alzheimer's disease drug Aduhelm and cut jobs.

The company is now counting on newer medicines such as a second approved Alzheimer's drug Leqembi, developed with Japanese partner Eisai, as well as Reata's Skyclarys to help drive growth.

© Reuters. FILE PHOTO: Biogen logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration/File Photo

The deal consists of $1.15 billion in upfront and up to $650 million in potential payments if felzartamab achieves certain development milestones.

The deal is expected to close in the third quarter, the companies said on Wednesday. HI-Bio is backed by investors such as biotech-focused ARCH Venture Partners and Monograph Capital.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.